Abstract: Disclosed herein is a composite superhydrophobic material comprising: a substrate layer comprising a set of positively or negatively charged functional groups; a metal nanoparticle coating on top of the substrate layer, comprising a set of negatively or positively charged functional groups; a metal layer on top of the metal nanoparticle coating; and a first superhydrophobic layer on top of the metal layer. Also disclosed herein is a method of making said material, and a method of predicting increased risk of spontaneous miscarriage using said material.

Abstract: Disclosed herein is a hydrogel that eradicates biofilm bacteria from wounds and accelerates diabetic wound healing. Also disclosed herein are methods of manufacture and use of said hydrogel.

Abstract: The invention relates to humanized antibodies directed against C-terminal Angiopoietin-like 4 protein (cANGPTL4) and uses thereof, such as their use in treating cancer and methods of cancer treatment.

Abstract: Disclosed herein is a polymeric material that includes a crosslinked polymer matrix formed from a non-mammalian collagen and a crosslinking agent and/or a crosslinked polymer matrix formed from a non-mammalian collagen that has undergone self-crosslinking, wherein the non-mammalian collagen is type I collagen. Also disclosed herein is a wound dressing that incorporates said material and methods of treatment of a wound with said polymeric material or said wound dressing.

Abstract: Disclosed herein is a hydrogel that eradicates biofilm bacteria from wounds and accelerates diabetic wound healing. Also disclosed herein are methods of manufacture and use of said hydrogel.

Abstract: Disclosed herein is a composite superhydrophobic material comprising: a substrate layer comprising a set of positively or negatively charged functional groups; a metal nanoparticle coating on top of the substrate layer, comprising a set of negatively or positively charged functional groups; a metal layer on top of the metal nanoparticle coating; and a first superhydrophobic layer on top of the metal layer. Also disclosed herein is a method of making said material, and a method of predicting increased risk of spontaneous miscarriage using said material.

Abstract: An antimicrobial polymer or hydrogel is provided. The antimicrobial polymer or hydrogel comprises a branched polyethylenimine (PEI) grafted with poly(ethylene glycol) methacrylate (PEGMA) of formula (I) or a branched polyethylenimine (PEI) grafted with poly(ethylene glycol) methacrylate (PEGMA) and decane of formula (II), wherein: m is an integer ranging from 1 to 20; n is an integer ranging from 1 to 20; in formula (I), the grafting ratio of PEI-PEGMA ranges from 1:1 to 1:20; and in formula (II), the grafting ratio of PEI-decane-PEGMA ranges from 1:1:1 to 1:20:20.

Abstract: A method and a pharmaceutical composition for increasing wound healing in an individual in need thereof, the method comprising administering an angiopoietin like 4 (ANGPTL4) polypeptide or a therapeutically active fragment thereof.

Abstract: The invention relates to the C-terminal fragment of angiopoietin-related protein 4 [cAngptl4] as a diagnostic marker for viral and bacterial pneumonia; anti-angiopoietin-related protein 4 therapeutic antibodies, and the use of anti-angiopoietin-related protein 4 antibodies in the treatment of viral and bacterial pneumonia.

Abstract: Vascular disruption induced by interactions between tumor-secreted permeability factors and adhesive proteins on endothelial cells facilitates metastasis. The role of tumor secreted angiopoietin-like 4 (cANG-PTL4) in vascular leakiness and metastasis is controversial due to the lack of understanding of how cANGPTL4 modulates vascular integrity. Here, we show that cANGPTL4 instigated the disruption of endothelial continuity by directly interacting with three novel binding partners, integrin ?5?1, VE-cadherin and claudin-5, in a temporally sequential manner, thus facilitating metastasis. We showed that cANGPTL4 binds and activates integrin ?5?1-mediated Rac1/PAK signaling to weaken cell-cell contacts. cANGPTL4 subsequently associated with and declustered VE-cadherin and claudin-5, leading to endothelial disruption. Interfacing with the formation of the cANGPTL4 complexes delayed vascular disruption.

Abstract: The invention provides an antibody specific to the ANGPTL4 protein capable of neutralizing proliferation and methods of making and using the same. The antibody of the invention is further directed to the C terminal region of the protein and may be capable of neutralizing cell proliferation and treating cancer. The antibody may be monoclonal and/or humanized antibody.

Abstract: A method and a pharmaceutical composition for increasing wound healing in an individual in need thereof, the method comprising administering an angiopoietin like 4 (ANGPTL4) polypeptide or a therapeutically active fragment thereof.

Abstract: A method and a pharmaceutical composition for increasing wound healing in an individual in need thereof, the method comprising administering an angiopoietin like 4 (ANGPTL4) polypeptide or a therapeutically active fragment thereof.

Abstract: The invention provides an antibody specific to the ANGPTL4 protein capable of neutralizing proliferation and methods of making and using the same. The antibody of the invention is further directed to the C terminal region of the protein and may be capable of neutralizing cell proliferation and treating cancer. The antibody may be monoclonal and/or humanized antibody.

Abstract: The invention relates to the C-terminal fragment of angiopoietin-related protein 4 [cAngptl4] as a diagnostic marker for viral and bacterial pneumonia; anti-angiopoietin-related protein 4 therapeutic antibodies, and the use of anti-angiopoietin-related protein 4 antibodies in the treatment of viral and bacterial pneumonia.

Abstract: A method and a pharmaceutical composition for increasing wound healing in an individual in need thereof, the method comprising administering an angiopoietin like 4 (ANGPTL4) polypeptide or a therapeutically active fragment thereof.

Abstract: Vascular disruption induced by interactions between tumor-secreted permeability factors and adhesive proteins on endothelial cells facilitates metastasis. The role of tumor secreted angiopoietin-like 4 (cANGPTL4) in vascular leakiness and metastasis is controversial due to the lack of understanding of how cANGPTL4 modulates vascular integrity. Here, we show that cANGPTL4 instigated the disruption of endothelial continuity by directly interacting with three novel binding partners, integrin ?5?1, VEcadherin and claudin-5, in a temporally sequential manner, thus facilitating metastasis. We showed that cANGPTL4 binds and activates integrin ?5?1-mediated Rac1/PAK signaling to weaken cell-cell contacts. cANGPTL4 subsequently associated with and declustered VE-cadherin and claudin-5, leading to endothelial disruption. Interfering with the formation of these cANGPTL4 complexes delayed vascular disruption.

Abstract: The invention provides an antibody specific to the ANGPTL4 protein capable of neutralizing proliferation and methods of making and using the same. The antibody of the invention is further directed to the C terminal region of the protein and may be capable of neutralizing cell proliferation and treating cancer. The antibody may be monoclonal and or humanized antibody.

Abstract: A universal secretory signal originally derived from a piscine vitellogenin (Vtg) gene is inserted into various expression vectors for driving the secretion of the recombinant protein into the culture medium. This enhances the detection, quantification and downstream scaled-up purification of a recombinant protein of interest. The secretory signal system is very versatile, being conveniently and widely applicable to an array of heterologous host cells such as bacteria, yeast, insect, piscine, and mammalian cell lines (e.g., COS, CHO, NIH/3T3). The said secretory system is also applicable as a reporter vector for secretion of reporter proteins/enzymes, thus, enabling the detection of the reporter proteins (e.g., CAT, GFP) in the culture medium.